BMS Presents Three Year Results from the P-III (POETYK PSO) LTE Trial of Sotyktu (deucravacitinib) for Moderate-to-Severe Plaque Psoriasis
Shots:
- The 3yr. results from the P-III LTE trial evaluating Sotyktu in 1221 adult patients with mod. to sev. PsO. At 148wk., clinical response rates were maintained at 73.2% with continuous treatment with mNRI responses for PASI 75; 48.1% for PASI 90 & 54.1% for sPGA 0/1
- The results showed a consistent safety profile with no increases in the rates of AEs or serious AEs over time and no emergence of any new safety signals were seen. Clinical efficacy outcomes were maintained from baseline through 148wk. with sustained response rates at 16 & 52wk. for PASI 75 (61.1% & 72.6%); PASI 90 (35.2% & 45.6%) and sPGA 0/1 (57.5% & 58.1%), respectively
- Cumulative exposure-adjusted incidence rates (EAIRs)/100 PYs were similar or decreased at 3yrs. over rates observed 2yrs., respectively
Ref: bristol-myers-squibb | Image: bristol-myers-squibb
Related News:- BMS’ Sotyktu (deucravacitinib) Receives EC’s Approval for the Treatment of Plaque Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
